GuruFocus
03 Jun 2026, 05:00 UTC · 2h ago
Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study
Search tags
GuruFocus
03 Jun 2026, 05:00 UTC · 2h ago
Search tags
Story key points
1 claims · impact-rated
Johnson & Johnson's nipocalimab significantly reduced disease activity in a Phase 2 trial for systemic lupus erythematosus (SLE). — Positive clinical data for a high-unmet-need autoimmune condition increases the probability of future drug approval and revenue growth.
+0.60Ticker attribution
Model heads
The company reported positive Phase 2 results for nipocalimab in treating systemic lupus erythematosus.
No ticker relationship head found.
Early access
News Impact Screener scores every headline against the stocks it moves — before the chart reacts. Join the early-access list and get alerted the moment a story hits your tickers.
Impact vectors
Continue reading
6 related stories
5 dimensions · 9 clusters
Market reaction
10 bid · 0 offered
No stock impact ranking available yet.
PRNewsWire
3h ago
